Synergy CHC (SNYR) Competitors $3.55 -0.31 (-8.03%) As of 08/14/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock SNYR vs. CGEN, LIMN, IMRX, MCRB, FATE, BHST, CNTB, SPRO, TARA, and SAVAShould you be buying Synergy CHC stock or one of its competitors? The main competitors of Synergy CHC include Compugen (CGEN), Liminatus Pharma (LIMN), Immuneering (IMRX), Seres Therapeutics (MCRB), Fate Therapeutics (FATE), BioHarvest Sciences (BHST), Connect Biopharma (CNTB), Spero Therapeutics (SPRO), Protara Therapeutics (TARA), and Cassava Sciences (SAVA). These companies are all part of the "pharmaceutical products" industry. Synergy CHC vs. Its Competitors Compugen Liminatus Pharma Immuneering Seres Therapeutics Fate Therapeutics BioHarvest Sciences Connect Biopharma Spero Therapeutics Protara Therapeutics Cassava Sciences Synergy CHC (NASDAQ:SNYR) and Compugen (NASDAQ:CGEN) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership. Does the media favor SNYR or CGEN? In the previous week, Compugen had 1 more articles in the media than Synergy CHC. MarketBeat recorded 8 mentions for Compugen and 7 mentions for Synergy CHC. Synergy CHC's average media sentiment score of 0.98 beat Compugen's score of 0.75 indicating that Synergy CHC is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Synergy CHC 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Compugen 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer SNYR or CGEN? Synergy CHC presently has a consensus target price of $10.00, suggesting a potential upside of 181.69%. Compugen has a consensus target price of $4.00, suggesting a potential upside of 175.86%. Given Synergy CHC's stronger consensus rating and higher possible upside, analysts plainly believe Synergy CHC is more favorable than Compugen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synergy CHC 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Compugen 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is SNYR or CGEN more profitable? Synergy CHC has a net margin of 0.00% compared to Compugen's net margin of -87.45%. Synergy CHC's return on equity of -8.48% beat Compugen's return on equity.Company Net Margins Return on Equity Return on Assets Synergy CHCN/A -8.48% 12.75% Compugen -87.45%-34.77%-16.82% Which has higher earnings and valuation, SNYR or CGEN? Synergy CHC has higher revenue and earnings than Compugen. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynergy CHC$34.83M0.94$2.12MN/AN/ACompugen$27.86M4.64-$14.23M-$0.22-6.59 Do insiders & institutionals hold more shares of SNYR or CGEN? 12.2% of Compugen shares are held by institutional investors. 56.6% of Synergy CHC shares are held by insiders. Comparatively, 9.5% of Compugen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummarySynergy CHC beats Compugen on 10 of the 13 factors compared between the two stocks. Get Synergy CHC News Delivered to You Automatically Sign up to receive the latest news and ratings for SNYR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNYR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNYR vs. The Competition Export to ExcelMetricSynergy CHCCONS PD IndustryStaples SectorNASDAQ ExchangeMarket Cap$35.49M$32.36B$16.16B$9.84BDividend YieldN/A2.59%3.07%4.07%P/E RatioN/A38.6119.0925.74Price / Sales0.942.0346.77115.79Price / Cash14.5116.6914.9559.48Price / Book-1.866.935.796.15Net Income$2.12M$1.23B$684.52M$265.06M7 Day Performance0.28%10.76%2.67%2.60%1 Month Performance4.41%11.83%0.67%2.83%1 Year PerformanceN/A27.82%4.93%25.58% Synergy CHC Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNYRSynergy CHC4.095 of 5 stars$3.55-8.0%$10.00+181.7%N/A$35.49M$34.83M0.0040News CoverageEarnings ReportHigh Trading VolumeCGENCompugen1.9847 of 5 stars$1.46flat$4.00+174.0%-17.1%$130.29M$27.86M-9.1370LIMNLiminatus PharmaN/A$4.93-3.1%N/AN/A$128.25MN/A0.00N/APositive NewsIMRXImmuneering3.7488 of 5 stars$3.53+2.9%$13.25+275.4%+181.5%$127.03MN/A-1.8060News CoverageEarnings ReportUpcoming EarningsAnalyst ForecastMCRBSeres Therapeutics3.2681 of 5 stars$14.51-1.9%$73.67+407.9%-6.7%$126.63M$126.32M-3.15330FATEFate Therapeutics4.0752 of 5 stars$1.09+2.4%$3.83+253.3%-67.3%$124.34M$13.63M-0.73550News CoverageEarnings ReportAnalyst ForecastBHSTBioHarvest SciencesN/A$7.55-1.6%$13.67+81.0%N/A$124.01M$27.70M-15.10N/ANews CoverageEarnings ReportAnalyst RevisionCNTBConnect Biopharma3.3425 of 5 stars$2.18+6.9%$7.00+221.1%+83.8%$121.12M$26.03M0.00110News CoverageAnalyst ForecastShort Interest ↓Analyst RevisionGap DownSPROSpero Therapeutics4.0526 of 5 stars$2.17-4.2%$5.00+130.9%+62.3%$121.05M$47.98M-1.69150Earnings ReportTARAProtara Therapeutics2.1706 of 5 stars$3.13-1.1%$20.50+556.0%+61.1%$120.56MN/A-1.8230Earnings ReportAnalyst RevisionSAVACassava Sciences2.0819 of 5 stars$2.47+7.6%$54.50+2,111.0%-89.8%$119.08MN/A-1.6430News CoverageEarnings ReportGap Down Related Companies and Tools Related Companies Compugen Competitors Liminatus Pharma Competitors Immuneering Competitors Seres Therapeutics Competitors Fate Therapeutics Competitors BioHarvest Sciences Competitors Connect Biopharma Competitors Spero Therapeutics Competitors Protara Therapeutics Competitors Cassava Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNYR) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synergy CHC Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synergy CHC With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access